July JAAD: Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy Phase 3 trial in the United States and Canada (BREEZE AD5)

AAD's Dialogues in Dermatology - En podcast af American Academy of Dermatology